"Disease Progression" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
| Descriptor ID |
D018450
|
| MeSH Number(s) |
C23.550.291.656
|
| Concept/Terms |
Disease Progression- Disease Progression
- Disease Progressions
- Progression, Disease
- Progressions, Disease
|
Below are MeSH descriptors whose meaning is more general than "Disease Progression".
Below are MeSH descriptors whose meaning is more specific than "Disease Progression".
This graph shows the total number of publications written about "Disease Progression" by people in this website by year, and whether "Disease Progression" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 7 | 7 |
| 1997 | 0 | 10 | 10 |
| 1998 | 0 | 15 | 15 |
| 1999 | 0 | 25 | 25 |
| 2000 | 0 | 22 | 22 |
| 2001 | 0 | 29 | 29 |
| 2002 | 0 | 24 | 24 |
| 2003 | 0 | 49 | 49 |
| 2004 | 0 | 31 | 31 |
| 2005 | 0 | 41 | 41 |
| 2006 | 0 | 41 | 41 |
| 2007 | 0 | 53 | 53 |
| 2008 | 0 | 44 | 44 |
| 2009 | 4 | 48 | 52 |
| 2010 | 4 | 55 | 59 |
| 2011 | 9 | 61 | 70 |
| 2012 | 4 | 65 | 69 |
| 2013 | 4 | 61 | 65 |
| 2014 | 6 | 63 | 69 |
| 2015 | 11 | 87 | 98 |
| 2016 | 6 | 73 | 79 |
| 2017 | 8 | 87 | 95 |
| 2018 | 7 | 88 | 95 |
| 2019 | 10 | 107 | 117 |
| 2020 | 6 | 85 | 91 |
| 2021 | 7 | 67 | 74 |
| 2022 | 0 | 39 | 39 |
| 2023 | 0 | 41 | 41 |
| 2024 | 20 | 37 | 57 |
| 2025 | 6 | 65 | 71 |
| 2026 | 0 | 16 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disease Progression" by people in Profiles.
-
Differences in gene expression may contribute to the racial differences in the risk of MASLD. PLoS One. 2026; 21(5):e0345383.
-
POD24 is a novel determinant of prognosis in patients with Waldenstr?m macroglobulinemia. Blood Adv. 2026 Apr 14; 10(7):2322-2327.
-
Predictive models for ataxia progression and conversion in spinocerebellar ataxia type 1 and 3. Brain. 2026 Apr 07; 149(4):1268-1277.
-
Progressive cardiac phenotypes and reduced reversibility from long-term CUGexp RNA expression in a DM1 mouse model. JCI Insight. 2026 May 08; 11(9).
-
Dynamic progression of ectopic lymphoid structure formation in lacrimal glands of a Sj?gren's disease murine model. Front Immunol. 2026; 17:1797691.
-
Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. JACC Heart Fail. 2026 Apr; 14(4):102943.
-
How to improve statistical power in a trial with SCA2 patients using natural history data. Trials. 2026 Mar 05; 27(1).
-
Children and Young People With First Relapse or Progression of Upfront Metastatic Rhabdomyosarcoma: An Analysis of Clinical Features and Outcomes From the INternational Soft Tissue saRcoma ConsorTium (INSTRuCT). Cancer Med. 2026 Mar; 15(3):e71524.
-
New approaches to uncover COPD pathobiology and develop therapies. JCI Insight. 2026 Feb 23; 11(4).
-
Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression. J Gastroenterol Hepatol. 2026 Mar; 41(3):1065-1076.